scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
October 10, 2022 08:00 ET
|
scPharmaceuticals, Inc.
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 ...
scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
September 30, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022 07:00 ET
|
scPharmaceuticals, Inc.
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of...
scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion
July 13, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
July 12, 2022 08:00 ET
|
scPharmaceuticals, Inc.
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4...
scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients
June 30, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting
June 07, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Present at the Jefferies Healthcare Conference
May 24, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...